biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs

Bullboard Posts

Post by Sinbobon Mar 18, 2012 11:45am

325 Views

Post# 19686721

Thought bubbles

Roche trades around $160/share, Abbott $50, Sanofi $38...as examples. For Roche to offer a share swap to BTI shareholders, it would be peanuts for them to issue say, 5 to 10 to 20 million shares. 5 million would be equivalent to about $20 for each BTI share, 10 million about $45, and 20 million about $90...for each BTI share.

Seems to me Roche could walk away laughing at a share swap of 5 million shares. Risky is right...think big.

Anecdotally, I once bought 20,000 shares of a stock in 1995 for $1/share...that was worth $32/share the following July on a buy out by Barrick gold. These things do happen.

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario